Nutritional safety and suitability of a specific protein hydrolysate derived from whey protein concentrate and used in an infant and follow-on formula manufactured from hydrolysed protein by Danone Trading ELN B.V

EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA)2021-05-122021-05-122020-11-28EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) 2020, 'Nutritional safety and suitability of a specific protein hydrolysate derived from whey protein concentrate and used in an infant and follow-on formula manufactured from hydrolysed protein by Danone Trading ELN B.V', EFSA Journal, vol. 18, no. 11, e06304. https://doi.org/10.2903/j.efsa.2020.63041831-4732PubMedCentral: PMC7698673ORCID: /0000-0002-9275-9713/work/99981875https://hdl.handle.net/2164/16453Acknowledgments: The Panel also wishes to thank the following EFSA staff members for the support provided to this scientific output: Domenico Azzolini, Ester Artau Cortacans, Federico Morreale, Charlotte Salgaard Nielsen and Ermolaos Ververis.121338457engProtein hydrolysatecharacterisationformulanutritional safetysuitabilityclinical trialinfantsR MedicineRNutritional safety and suitability of a specific protein hydrolysate derived from whey protein concentrate and used in an infant and follow-on formula manufactured from hydrolysed protein by Danone Trading ELN B.VJournal article10.2903/j.efsa.2020.63041811